Semaglutide Treatment On Coronary Progression
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.
Also called NCT03985384
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Registry
-
NCT03985384
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03985384. Randomized; quadruple masking; primary purpose treatment. Start 2019-04-30 (actual); primary completion 2022-12-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Semaglutide Treatment On Coronary Progression
- Acronym
- STOP
- Condition
- Type 2 Diabetes
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Record details
- Record id
cardio:ct-nct03985384- Content hash
401212d22d9f10deb51cba66729931d784a2b6bc32b030ad28a08cff85acd3fc